Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
根据最新的财务报表(Form-10K),ABIVAX Société Anonyme 的总资产为 $0,净亏损为 $0
ABVX 的关键财务比率是什么?
ABIVAX Société Anonyme 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
ABIVAX Société Anonyme 的收入按细分市场或地理位置如何划分?
ABIVAX Société Anonyme 最大收入来源是 High-Touch Solutions N.A.,在最近的收益报告中收入为 13,993,000,000。就地区而言, United States 是 ABIVAX Société Anonyme 的主要市场,收入为 14,441,000,000。